AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23547849
Drug: Tocilizumab 324
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 324 mg with rHuPH20
Trial: 23547849
Drug: Tocilizumab 648
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 648 mg with rHuPH20
Trial: 23547849
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of tocilizumab
Trial: 21714883
Drug: Care management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care management intervention involving comprehensive assessment of medical and non-medical needs, regular structured monitoring of symptoms, written information, symptom diaries, action plans, and a medication plan for self-management capabilities.
Trial: 12390096
Drug: Tegaserod, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod, 6 mg b.d. (n = 767)
Trial: 10191213
Drug: Candidate HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate HIV-1 vaccine
Trial: 2263428
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (52 doses)
Trial: 2263428
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (94 doses)
Trial: 30109443
Drug: G‐Premio Bond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Premio Bond (GP)
Trial: 23605128
Drug: Electrical Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Stimulation Therapy (EST) on the suprahyoid muscle only (SM)
Trial: 23605128
Drug: Electrical Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Stimulation Therapy (EST) with one pair of electrodes on the suprahyoid muscle and another pair on the infrahyoid muscle (SI)
Trial: 9517646
Drug: 4-day low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-day low dose triple therapy (LAT group): lansoprazole 30 mg b.i.d. on days 1-4, azithromycin 500 mg u.i.d. on days 2-4, tinidazole 2000 mg u.i.d. on day 3
Trial: 9517646
Drug: 1-week triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week triple therapy (OCT group): omeprazole 20 mg u.i.d., clarithromycin 250 mg b.i.d., tinidazole 500 mg b.i.d.
Trial: 3132244
Drug: Combined oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oestrogen and progestogen (sequential supplementation)
Trial: 29191714
Drug: Subcutaneous immunoglobulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulins
Trial: 28176220
Drug: Intravenous glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucocorticoids (ivGCs) - methylprednisolone with cumulative doses of 2.25, 4.98, 7.47 g
Trial: 21934371
Drug: P group
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P group (random surface tilt perturbations, 3 times weekly for 3 weeks)
Trial: 21934371
Drug: P+EX group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P+EX group (random surface tilt perturbations + home vestibular rehabilitation exercises, 3 times weekly for 3 weeks)
Trial: 19145673
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ketoprofen i.v. every 8h for 72h
Trial: 19145673
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g metamizole i.v. every 8h for 72h
Trial: 12042687
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (n = 77)
Trial: 1940775
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg nightly in non-FH patients
Trial: 1940775
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg nightly in FH patients
Trial: 1940775
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg nightly in pooled patients (n = 224)
Trial: 19056606
Drug: L-carnitine 2
RxNorm normalized name: L-Carnitine 250mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 2 g once daily
Trial: 11486790
Drug: Orlistat (OLS)
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat (OLS) 120 mg three times daily
Trial: 9349964
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with 'Flowtron DVT' garments followed by Enoxaparin
Trial: 8252746
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen (1.25 mg Premarin)
Trial: 8252746
Drug: Oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol valerate (2 mg)
Trial: 3545477
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg metolazone
Trial: 3545477
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg metolazone
Trial: 3545477
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg metolazone
Trial: 3545477
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg older metolazone
Trial: 30706426
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec U100
Trial: 24891437
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (FCM) targeting high ferritin (400-600 µg/L)
Trial: 24891437
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (FCM) targeting low ferritin (100-200 µg/L)
Trial: 20308250
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) infusion at 125 mg kg(1) h(1) for 15 min and then at 25 mg kg(1) h(1) for 20 min before and throughout exercise
Trial: 12470771
Drug: Bradykinin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin (10 microg intradermal injection)
Trial: 30045423
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with beverage powder containing 7 mg isotopically labeled iron (57Fe/58Fe) as Fe4(P2O7)3 and equimolar proportions of ascorbic acid
Trial: 24615745
Drug: AC (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (100 mg aspirin plus 75 mg clopidogrel)
Trial: 24615745
Drug: ACH (AC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH (AC plus 20 mg famotidine twice-daily)
Trial: 23073360
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of MgCl2 5% solution (equivalent to 382 mg of magnesium), daily for three months
Trial: 20963535
Drug: Romiplostim (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (0.3, 1 and 10 μg/kg intravenous; 0.1, 0.3, 1, and 2 μg/kg subcutaneous)
Trial: 20963535
Drug: Weekly dosing
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dosing of Romiplostim
Trial: 20963535
Drug: Dosing intervals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing intervals ≥2 weeks of Romiplostim
Trial: 11013539
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dialogues about daily events)
Trial: 8780818
Drug: Nevirapine plus
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine plus ZDV (200 mg daily for 2 weeks followed by 200 mg twice daily for 26 weeks)
Trial: 21137649
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg IM
Trial: 15704485
Drug: Cerebrolysin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin 30 ml
Trial: 2222131
Drug: Fluoxetine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine for 10 weeks
Trial: 2222131
Drug: Fluoxetine after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine after clomipramine
Trial: 2222131
Drug: Clomipramine after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine after fluoxetine
Trial: 29179761
Drug: Xingnao Kaiqiao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnao Kaiqiao acupuncture via intradermal needling
Trial: 24373419
Drug: Immediate load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate load post-extractive implant with subepithelial connective tissue graft (grafted group)
Trial: 24373419
Drug: Immediate load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate load post-extractive implant without raising a flap (non-grafted group)
Trial: 23880005
Drug: Pemetrexed (PEM)
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed (PEM) 500 mg/m² on day 1 + Carboplatin (CBP) AUC5 on day 1 for 21-day cycle
Trial: 23880005
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m² on days 1 and 8 + Carboplatin (CBP) AUC5 on day 1 for 21-day cycle
Trial: 20805741
Drug: Concurrent radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiation treatment
Trial: 20805741
Drug: Sequential radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiation treatment
Trial: 17035647
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean dose, 5.5 mg per day)
Trial: 17035647
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean dose, 56.5 mg per day)
Trial: 17035647
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose, 1.0 mg per day)
Trial: 12854452
Drug: Best proven
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best proven therapy
Trial: 8723575
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (600 IU/kg twice weekly for 3 weeks)
Trial: 6341847
Drug: Intramuscular penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular penicillin G given within 60 minutes of birth
Trial: 6341847
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no penicillin treatment)
Trial: 6341847
Drug: Intramuscular penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular penicillin G
Trial: 28640389
Drug: PF plus
RxNorm normalized name: GLYCERIN 0.25 g in 100 mL OPHTHALMIC SOLUTION/ DROPS [Oasis TEARS PF PLUS Preservative-Free Lubricant Eye]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF plus 10 μg/m2 daily rhLTα‐Da
Trial: 28640389
Drug: PF plus
RxNorm normalized name: GLYCERIN 0.25 g in 100 mL OPHTHALMIC SOLUTION/ DROPS [Oasis TEARS PF PLUS Preservative-Free Lubricant Eye]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF plus 20 μg/m2 daily rhLTα‐Da
Trial: 21790794
Drug: Topical CPS
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical CPS (1% cantharidin, 5% podophyllotoxin, 30% salicylic acid)
Trial: 15065029
Drug: Erythromycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (3 mg/kg/dose 4 times daily)
Trial: 10463321
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine infusion (bolus of 0.26 mg/kg followed by 0.65 mg/kg per hour) with oral haloperidol 5 mg
Trial: 10463321
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine infusion (bolus of 0.26 mg/kg followed by 0.65 mg/kg per hour) with matched placebo
Trial: 8667595
Drug: Antineoplaston A-10
RxNorm normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antineoplaston A-10 oral formulation (14 patients)
Trial: 8667595
Drug: Antineoplaston A-10
RxNorm normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antineoplaston A-10 injectable formulation (25 patients)
Trial: 8667595
Drug: Antineoplaston AS2-1
RxNorm normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antineoplaston AS2-1 oral formulation (33 patients)
Trial: 8667595
Drug: Antineoplaston AS2-1
RxNorm normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antineoplaston AS2-1 injectable formulation (10 patients)
Trial: 8667595
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Antineoplastons
Trial: 841647
Drug: BCG vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccination (intrademal injection)
Trial: 25283137
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of chloral hydrate (CH) for five consecutive days
Trial: 25283137
Drug: 1.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 μg/kg of chloral hydrate (CH) for five consecutive days (environmental dose)
Trial: 23348836
Drug: Topical 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-fluorouracil
Trial: 20797824
Drug: Short neoadjuvant
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short neoadjuvant hormonal therapy (4 months; Arm 1)
Trial: 20797824
Drug: Long neoadjuvant
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long neoadjuvant hormonal therapy (8 months; Arm 2)
Trial: 16890660
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg) with bacillus Calmette‐Guerin
Trial: 7970086
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (protein restriction, antihypertensive therapy)
Trial: 7970086
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of treatment vs control
Trial: 2451494
Drug: 0.1% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% sodium hyaluronate artificial tear preparation
Trial: 2451494
Drug: 1.4% polyvinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4% polyvinyl alcohol and 0.5% chlorobutanol artificial tear preparation
Trial: 31702992
Drug: Anodal high-voltage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal high-voltage monophasic pulsed currents (HVMPC) treatment (154 μs; 100 Hz; 360 µC/sec; 1.08 C/day) for 50 minutes a day, 5 days per week, for 8 weeks.
Trial: 31702992
Drug: Cathodal high-voltage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal high-voltage monophasic pulsed currents (HVMPC) treatment (154 μs; 100 Hz; 360 µC/sec; 1.08 C/day) for 50 minutes a day, 5 days per week, for 8 weeks.
Trial: 31702992
Drug: Placebo (sham)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham) treatment for 50 minutes a day, 5 days per week, for 8 weeks.
Trial: 28445474
Drug: COACH program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COACH program (medication reconciliation, patient counselling at discharge, communication to healthcare providers)
Trial: 26007320
Drug: Condori red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condori red grapes (500 g daily for 8 weeks)
Trial: 26007320
Drug: Shahroodi white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shahroodi white grapes (500 g daily for 8 weeks)
Trial: 24001950
Drug: G-Bond (self-etching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Bond (self-etching adhesive)
Trial: 21959045
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus mIFL (irinotecan 125 mg/m², leucovorin 20 mg/m² bolus, 5-fluorouracil 500 mg/m² weekly for four weeks every six weeks)
Trial: 21959045
Drug: mIFL (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mIFL (irinotecan 125 mg/m², leucovorin 20 mg/m² bolus, 5-fluorouracil 500 mg/m² weekly for four weeks every six weeks)
Trial: 12484510
Drug: Benazepril 5
RxNorm normalized name: benazepril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 5 mg daily (normal dose) in patients with LVH
Trial: 12484510
Drug: Benazepril 2.5
RxNorm normalized name: amlodipine-benazepril 2.5 mg-10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 2.5 mg daily (half dose) in patients without LVH
Trial: 12484510
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of ACE inhibitor in patients with or without LVH
Trial: 9771173
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow rates of 1, 2 or 3 l.min‐1
Trial: 383097
Drug: 3 times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day 3 mg haloperidol (3-day group)
Trial: 383097
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg haloperidol only in the evening (1-day group)
Trial: 31392827
Drug: Betrixaban 80
RxNorm normalized name: betrixaban 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betrixaban 80 mg qd for 35 to 42 days
Trial: 31493287
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg qd for 10 ± 4 days
Trial: 20022809
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2 intravenously) plus Docetaxel (60 mg/m2 intravenously)
Trial: 17710370
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (GlaxoSmithKline Biologicals)
Trial: 17710370
Drug: MMR+V (Priorix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR+V (Priorix and Varilrix vaccines)
Trial: 14713758
Drug: Phase 2
RxNorm normalized name: Premphase 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 clinical trials of various agents
Trial: 11781276
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg daily for 8 weeks
Trial: 2483445
Drug: Ibopamine, digitalis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine, digitalis, and diuretics
Trial: 2483445
Drug: Placebo, digitalis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, digitalis, and diuretics
Trial: 28698169
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine offering (DMO) for 4 weeks
Trial: 28698169
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine offering (DMO) for 12 weeks
Trial: 28698169
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine offering (DMO)
Trial: 21561620
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (2.4 g/day of EPA and DHA for 6 weeks)
Trial: 21561620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of statins and n-3 fatty acids
Trial: 18427130
Drug: Aggressive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive lipid-lowering therapy
Trial: 10325756
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily growth hormone injections (6 IU/m2/day)
Trial: 10325756
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily growth hormone injections (6 IU/m2/day)
Trial: 10325756
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (once daily and twice daily) with low dose ethinyl oestradiol (0.05 microgram/kg/day, increased to 0.10 microgram/kg/day after 2.25 years)